Multiple Sclerosis
We recommend
Balance and Rehabilitation – Firm on the Ground Even with Multiple Sclerosis
A large portion of patients with multiple sclerosis (MS) suffer from balance disorders. What are the options for non-pharmacological therapy for these issues according to the latest studies?
Neutropenia with Thrombocytopenia after Alemtuzumab? − Case Report
Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the…
MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information
How to offer a helping hand to patients amidst the flood of information and why is communication…
Articles on this topic
Alemtuzumab – Does Age Matter? Or Not?
The authors of a study published this year focused on the safety and efficacy of alemtuzumab…
Does Teriflunomide Bloom at Every Age?
What impact does age have on the effectiveness of multiple sclerosis (MS) therapy in…
Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?
Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of...
MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?
What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases...
How did alemtuzumab fare in real clinical practice?
A study published by authors from the University of Massachusetts in January this year in the…
COVID-19 and MS: Do You Know the Risk Factors? What the American Registry Analysis Showed
An article published in the March issue of the prestigious journal JAMA Neurology summarizes…
Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?
An article by French authors published in January this year in the journal Multiple Sclerosis…
Teriflunomide and Pregnancy Planning
The authors of the article published last year in Multiple Sclerosis Journal present data…
Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal…
Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Ketogenic diet in MS patients as an aid to increase microbiota diversity and quantity
- Assessment of Infection Risk in Patients with Multiple Sclerosis Treated with Various DMDs
- COVID-19 and MS: Do You Know the Risk Factors? What the American Registry Analysis Showed
- Epstein-Barr Virus – Is the Culprit of MS Revealed?
- Gut-Brain Axis − Future of MS Treatment?
- Induction vs. Escalation Treatment: Which Strategy to Choose in the Therapy of Multiple Sclerosis?
Journal on this topic
Related topic